scPharmaceuticals Inc. Announces Results of Type A End-of-Review Meeting with FDA Regarding FUROSCIX® NDA
Last scpharmaceuticals, inc earnings: 3/24 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations: scpharmaceuticals.com
No additional clinical efficacy, PK or safety data required December 31, 2020 cash, cash equivalents, restricted cash and investments estimated to be $105 million, sufficient to fund operations through potential FUROSCIX® approval and launch and into 2023 BURLINGTON, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that on February 19, 2021, the Company received the official Type A meeting minutes from the U.S. Food and Drug Administration (FDA) regarding the requirements for resubmission of the FUROSCIX® 505(b)(2) New Drug Application (NDA) following the Complete Response Letter (CRL) received on December 3, 2020. The outstanding questions are primarily focused on Pre-Approval Inspections and bench testing. The Company will run additiona
[Read more]
| Impact snapshot | Event time: | SCPH | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
SCPH alerts
SCPH alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SCPH alerts
High impacting scPharmaceuticals, Inc news events
Weekly update
A roundup of the hottest topics
SCPH
News
- scPharmaceuticals to Present in Two Upcoming Investor ConferencesGlobeNewswire
- scPharmaceuticals Inc. Appoints Renowned Heart Failure Specialist William T. Abraham, M.D., to its Board of DirectorsGlobeNewswire
- scPharmaceuticals to Present at the 10th Annual SVB Leerink Global Healthcare ConferenceGlobeNewswire
- scPharmaceuticals Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/SCPH/price-target/">NASDAQ: SCPH</a>) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating.MarketBeat
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of scPharmaceuticals Inc. - SCPHPR Newswire
- More
SCPH
SEC Filings
- 2/23/21 - Form 8-K
- 2/17/21 - Form 4
- 2/17/21 - Form 3
- SCPH's page on the SEC website
- More